B-lymphocyte stimulator (BLyS) plays a critical role in the survival of B-lymphocytes. In 50 patients with Hodgkin's lymphoma BLyS levels were higher in newly diagnosed patients (median 2.0 ng/mL, range <0.3-56.0) and relapsed patients (8.7 ng/mL, range 1.5-71.5) than in 93 healthy donors (<0.3 ng/mL, range <0.3-0.5). High serum BLyS levels (≥ ≥2.0 ng/mL) in newly diagnosed patients were associated with resistance to therapy (p=0.01) and shorter progression-free survival (log-rank p=0.029, 2-year rate 64% vs 100%). Serum BLyS levels may have prognostic significance in Hodgkin's lymphoma. Haematologica 2007; 92: 269-270 
Recent in vitro experiments demonstrated that BLyS was also expressed by Reed-Sternberg cells of Hodgkin's lymphoma (HL) as well as the reactive infiltrate of HL, such as macrophages, granulocytes and plasma cells, serving as an important survival factor for malignant cells. 8 Here we examined the serum levels of BLyS in patients with HL, and evaluated their prognostic value.
Serum samples were obtained from 93 healthy volunteers and 50 patients with HL (25 at initial diagnosis and 25 at relapse). The patients' samples were deposited in the M. D. Anderson Cancer Center Lymphoma Serum Bank. All patients and volunteers gave consent to blood donation in accordance with the Institutional Review Board guidelines. Serum levels of BLyS were measured by enzyme-linked immunosorbent assay (ELISA) using a monoclonal murine antibody as the capture reagent and a goat polyclonal antibody as the detector. 9 The lower limit of detection of the assay is 0.3 ng/mL. Serum BLyS levels were correlated with responses to initial therapy, progression-free survival (PFS), and overall survival (OS). PFS was calculated from the date of blood drawing (either at initial diagnosis or relapse) to the date of observed disease progression or death. Fisher's exact test and the Mann-Whitney test were used for comparisons of categorical and continuous data, respectively. Survival curves were estimated according to the KaplanMeier method, and the two groups were compared by the log-rank test.
The levels of BLyS in healthy individuals ranged from <0.3 to 0.5 ng/mL, with a median value of <0.3 ng/mL ( Figure 1A ). Serum BLyS levels were elevated in patients with newly diagnosed HL (median 2.0 ng/mL, range <0.3-56.0, p<0.0001) and were even higher in relapsed patients (median 8.7 ng/mL, range 1.5-71.5, p<0.0001). In newly diagnosed patients, a high BLyS level (≥2.0 ng/mL) was associated with other unfavorable characteristics including male sex (p=0.02), stage 4 disease (p=0.07), bulky disease ≥7.5cm (p=0.03), high lactate dehydrogenase (LDH) (p<0.01), high β2 microglobulin (p=0.01), and a less than complete response to treatment (p=0.01) ( Table 1 ).
All newly diagnosed patients with HL were treated with three to six cycles of ABVD chemotherapy with or without radiation therapy. The median follow-up duration was 53.3 months (range 9.6-80.2). Patients with serum BLyS levels ≥2.0 ng/mL had a shorter PFS than those with BLyS levels <2.0 ng/mL, with 2-year PFS rates of 64% and 100%, respectively (log-rank p=0.029, Figure 1B) . The same trend was observed by analysis using the third quartile value (5.3 ng/mL) as a cut off, but the differences were not statistically significant (p=0.19). By univariate analyses (separate logrank tests) for PFS in patients with newly diagnosed HL among seven known unfavorable prognostic factors 10 [age >45 years, male sex, stage 4 disease, WBC ≥1.5×10 
